NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION
NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide